Navigation Links
Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
Date:9/11/2008

EMERYVILLE, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its fiscal 2008 fourth quarter and year-end financial results on September 16, 2008.

The Company will also host a call to discuss its financial results. Details for the fiscal year-end call are as follows:

-- Date: Tuesday, September 16, 2008

-- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT

-- Dial-in number: 877-874-1565 U.S. & Canada / 719-325-4822 International

The web cast can be accessed online at: http://investor.shareholder.com/ntii/events.cfm

Telephonic Replay: A playback of the conference call will be available from 1:30 pm (ET) on September 16, 2008 to midnight (ET) on September 23, 2008. Reply number: 888-203-1112 U.S. / 719-457-0820 International Pass code: 2312764

The presentation at the Merriman Curhan Ford Investor Summit will take place on Monday, September 15, 2008 at 10:15 a.m. at the Mark Hopkins InterContinental Hotel in San Francisco. Access to the presentation can be found at: http://investor.shareholder.com/ntii/events.cfm

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies CEO to Retire on December 31, 2008
3. Neurobiological Technologies Reports Third Quarter Financial Results
4. Neurobiological Technologies Sets Date for Third Quarter Financial Results
5. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
6. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
7. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
8. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
9. Neurobiological Technologies Sets Date for Research and Development Day
10. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
11. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Francisco, CA (PRWEB) , ... ... ... leader uBiome is opening applications to an early access program for SmartBiome ... of metagenomic deep-sequencing with the simultaneous specific enrichment and detection of hundreds ...
(Date:12/6/2016)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today ... fiscal year ended September 30, 2016. ... , , SQI ... company that develops and commercializes proprietary technologies and products for advanced ... revenues of $1.4 million more than tripling prior years revenue. ...
(Date:12/6/2016)... ... ... Discovering new clues to natural treatments that could allow our bodies to ... And searching for keys to our immune systems by studying parasite-resistant fish. These are ... Edith and Peter O’Donnell Awards by The Academy of Medicine, Engineering and ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... Point Partners ("GPP") portfolio company, today announced it has acquired the assets ... subsidiary of Chiltern International and focuses on clinical trial drug packaging, labeling, ...
Breaking Biology Technology:
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):